Your browser doesn't support javascript.
loading
Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists.
Skudlarek, Jason W; DiMarco, Christina N; Babaoglu, Kerim; Roecker, Anthony J; Bruno, Joseph G; Pausch, Mark A; O'Brien, Julie A; Cabalu, Tamara D; Stevens, Joanne; Brunner, Joseph; Tannenbaum, Pamela L; Wuelfing, W Peter; Garson, Susan L; Fox, Steven V; Savitz, Alan T; Harrell, Charles M; Gotter, Anthony L; Winrow, Christopher J; Renger, John J; Kuduk, Scott D; Coleman, Paul J.
  • Skudlarek JW; Department of Medicinal Chemistry, MRL, Merck & Co., Inc., West Point, PA 19486, USA. Electronic address: jason_skudlarek@merck.com.
  • DiMarco CN; Department of Medicinal Chemistry, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Babaoglu K; Department of Chemical Capabilities & Screening, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Roecker AJ; Department of Medicinal Chemistry, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Bruno JG; Department of In Vitro Pharmacology, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Pausch MA; Department of In Vitro Pharmacology, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • O'Brien JA; Department of In Vitro Pharmacology, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Cabalu TD; Department of Drug Metabolism, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Stevens J; Department of In Vivo Pharmacology, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Brunner J; Department of Neuroscience, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Tannenbaum PL; Department of In Vivo Pharmacology, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Wuelfing WP; Discovery Pharmaceutical Sciences, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Garson SL; Department of Neuroscience, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Fox SV; Department of In Vivo Pharmacology, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Savitz AT; Department of In Vivo Pharmacology, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Harrell CM; Department of Neuroscience, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Gotter AL; Department of Neuroscience, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Winrow CJ; Department of Neuroscience, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Renger JJ; Department of Neuroscience, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
  • Kuduk SD; Novira Therapeutics, Inc., a part of Janssen Pharmaceuticals, Doylestown, PA 18902, USA(1).
  • Coleman PJ; Department of Medicinal Chemistry, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
Bioorg Med Chem Lett ; 27(6): 1364-1370, 2017 03 15.
Article en En | MEDLINE | ID: mdl-28216403
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Orexinas / Antagonistas de los Receptores de Orexina Límite: Animals Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Orexinas / Antagonistas de los Receptores de Orexina Límite: Animals Idioma: En Año: 2017 Tipo del documento: Article